ASC09F / Ascletis - LARVOL DELTA

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection (clinicaltrials.gov) - P=N/A | N=6 | Terminated | Sponsor: First Affiliated Hospital of Zhejiang University | N=160 ➔ 6 | Not yet recruiting ➔ Terminated; There were no more subjects enrolled.

Enrollment change • Trial termination • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Ascletis Pharmaceuticals Co., Ltd.; Not yet recruiting ➔ Completed; Trial completion date: Jan 2024 ➔ Dec 2020

Clinical • Trial completion • Trial completion date

Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH (PRNewswire) - "Ascletis Pharma Inc....announces today that the board of directors of the Company (the 'Board') resolved to change the use of the remaining Net Proceeds from the Global Offering....The Company intends to reduce from approximately 25% to 18% of this portion of the Net Proceeds and re-allocate mainly to continued research and development of the Core Product pipeline in...HIV/AIDS....ASC09F is a FDC treatment of HIV targeting protease. The clinical trial application of ASC09F has been approved."

Commercial • Regulatory • Human Immunodeficiency Virus

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Ascletis Pharmaceuticals Co., Ltd.

Clinical • New P1 trial

The Antiviral and Antimalarial Drug Repurposing in Quest of Chemotherapeutics to Combat COVID-19 Utilizing Structure-Based Molecular Docking. (PubMed, Comb Chem High Throughput Screen) - "Our in silico docking results have been confirmed by current reports from clinical settings through the citation of suitable experimental in vitro data available in the published literature."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology

A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia (clinicaltrials.gov) - P3; N=60; Recruiting; Sponsor: Tongji Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Coronavirus puts drug repurposing on the fast track (PRNewswire) - "Chinese authorities are testing two HIV protease inhibitors (ritonavir and ASC09) in clinical trials to treat COVID-19, the illness caused by the new coronavirus…and others originally developed to treat Ebola virus and then dropped, will also be tested by private western companies in partnership with Chinesehealth authorities in randomized, controlled trials."

Clinical

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection (clinicaltrials.gov) - P=N/A; N=160; Not yet recruiting; Sponsor: First Affiliated Hospital of Zhejiang University

Clinical • New trial

A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia (clinicaltrials.gov) - P3; N=60; Not yet recruiting; Sponsor: Tongji Hospital

Clinical • New P3 trial